GW Pharmaceuticals (GWP)

Business description

GW Pharmaceuticals is a UK-based speciality pharma company focused on developing cannabinoid medicines. Lead product, Sativex, is marketed in a number of European countries for multiple sclerosis-associated spasticity.

Share price chart

Share chart

Stock data

Market cap.£1085.4m
Last close462.25p
High / Low (52 weeks)523.5p / 75.0p
Stock market listingLN, US
Forecast net cash (£m)79
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual5.47.8551.1
Relative *4.37.6531.2

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Alnylam Pharmaceuticals Amarantus BioScience
Amarin AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Arena Pharmaceuticals
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
AVEO Pharmaceuticals Avita Medical
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioAlliance Pharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BTG
Can-Fite BioPharma Capstone Therapeutics
Cardio3 BioSciences CARMAT
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MolMed Mologen AG
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon Pharmacyclics
Pharmaxis Pharming Group
Photocure Phylogica
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Regeneus
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis Synairgen
Synergy Health Synta Pharmaceuticals
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals UCB
uniQure NV United Drug
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology

Company news

5 Things That Marijuana Stock GW Pharmaceuticals plc's Management Wants ...

Thu, 28 Aug 2014 20:48:45 GMT

Director Deals - GW Pharmaceuticals PLC (GWP)

Fri, 29 Aug 2014 11:48:45 GMT

Investors Are Watching: Micron Technology (NASDAQ:MU), GW ...

Wed, 10 Sep 2014 12:54:52 GMT

Stock Update: GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

Fri, 22 Aug 2014 15:22:30 GMT

Trader's Watch List : Yelp (NYSE:YELP), GW Pharmaceuticals plc (NASDAQ ...

Thu, 21 Aug 2014 13:15:16 GMT

Y/E Sep Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2012A 33.1 2.8 2.2 2.6 177.8 447.8
2013A 27.3 (8.9) (9.7) (2.6) N/A N/A
2014E 24.5 (19.4) (19.6) (7.6) N/A N/A
2015E 28.6 (11.6) (12.0) (3.7) N/A N/A

Last updated on 28/08/2014

Investment summary

GW Pharmaceuticals’ pipeline should deliver important, potentially transformative clinical data during H214. Major inflection points include Phase III cancer pain data (Q414) and US Phase III start in MS spasticity (H214/H115) for lead programme Sativex, as well as further interim updates from the ongoing physician-led open-label studies of Epidiolex in refractory childhood epilepsies, ahead of a placebo-controlled Phase II/III trial in Dravet Syndrome in Q414. GW will also host an R&D day in New York on 14 October, which will provide a detailed review of the profile and progress of products in its cannabinoid pipeline. FY14 guidance was reiterated at Q314 results: strong double-digit growth in Sativex sales is expected, with increased GW-funded R&D spend, and closing cash of £150-155m. End-Q314 (June) cash and equivalents stood at £168.3m.

Last updated on 01/09/2014

Industry outlook

GW is the leader in the field of cannabinoid medicines, which have the potential to become novel therapies for a broad range of diseases. Cannabinoids are diverse chemical compounds that GW extracts from different cannabis plant varieties (chemotypes) it has bred.

Last updated on 01/09/2014

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website